U.S. Supreme Court Declines to Hear 280E Challenge Over Late Paperwork

The U.S. Supreme Court has declined to hear an appeal case by California cannabis companies that sought to challenge their tax bills after filing their petitions with the U.S. Tax Court one day after the deadline, Law360 reports. Organic Cannabis Foundation LLC and Northern California Small Business Assistants Inc are fighting a $1.9 million tax bill — the result of filing under Section 280E, which prohibits tax deductions for companies trafficking in a controlled substance.

Cannabis companies throughout the U.S. must file under 280E because cannabis remains federally illegal.

The companies – both owned by Dona Ruth Frank – argued that under the precedent set by a Supreme Court decision in 2015, statutory deadlines are presumptively non-jurisdictional and therefore subject to equitable tolling. The companies’ case challenged the constitutionality of the 280E provisions, the report says.

The Ninth Circuit had ruled in June that the Tax Court was correct in dismissing the case based on the lack of jurisdiction.

In a separate case, the Tax Court ruled in February that San Jose Wellness, a subsidiary of Harborside, was liable for $4.2 million in taxes because federal law prohibits it from claiming depreciation and charitable contribution deductions due to 280E. In that case, Judge Emin Toro said that the “requirements of Section 280E are clear.”

Last month, the U.S. Circuit Court of Appeals rejected the 280E appeal from Oakland-based Patients Mutual Assistance Collective Corp – or Harborside Health Center – ruling that federal cannabis prohibition prevents legal cannabusiness from excluding or deducting taxable income as business expenses.

Last year, the Supreme Court declined to hear the case challenging the constitutionality of federal cannabis prohibition and the Drug Enforcement Agency’s Schedule I classification.

End


New York City Taxi Commission Stops Drug Testing for Cannabis

The New York City Taxi & Limousine Commission (TLC) will no longer test drivers for cannabis following statewide legalization enacted in March, according to a memo obtained and outlined by the New York Post.

TLC licenses drivers for the city’s livery vehicles, along with Uber and Lyft drivers. According to the commission’s website, the agency has over 200,000 licensees.

In an interview with the Post, Fernando Mateo, founder and spokesman of the New York State Federation of Taxi Drivers, called the move “a big mistake” and “irresponsible.”

“If they’re not going to be testing for marijuana, that means drivers will have the opportunity to smoke weed and drive. I don’t want my kids in a car with a guy that smokes weed, and is allowed to smoke weed regularly, and not get tested. We have to draw the line somewhere.” – Mateo to the Post

New York’s legalization law includes language allowing stoned drivers to be charged with driving while intoxicated. In the memo, TLC said that “while the use of marijuana is now legal for adults, it is still the law that TLC-licensed Drivers must be sober when they operate a vehicle.” The agency also noted that testing for other illegal drugs would remain unchanged.

In states that have legalized cannabis for adult-use, employment drug testing changes sometimes follow either statewide or through changes at private companies. In Maine, Bath Iron Works and Maine Health – the state’s largest private employer – indicated they would no longer test employees for cannabis use as part of their employment practices.

The National Football League – which is headquartered in New York City – announced in March that it would shorten its window for cannabis testing and would no longer suspend players for a positive cannabis test. Thirteen of the league’s 32 teams are from states that have legalized cannabis.

End


Swiss Parliamentary Committee Votes to Legalize Cannabis

Switzerland came one step closer to adult-use cannabis legalization after lawmakers in the Health Commission of Switzerland’s National Council, the country’s lower legislative body, voted 13-11 on Friday in favor of a plan that would legalize cannabis access for adults, according to a Zürichsee-Zeitung report.

The parliamentary initiative was proposed by National Council Member Heinz Siegenthaler and seeks to expand the country’s current adult-use cannabis pilot program — which was approved last September and legalized access for some 5,000 registered study participants — to include all adults. Under that program, distributed cannabis must be organic and produced in Switzerland; additionally, THC content is capped at 20% for the pilot program’s cannabis products and the products must come in child-resistant packaging with appropriate safety warnings and accurate cannabinoid content displayed on the label.

When presenting his proposal, Siegenthaler argued that federal cannabis prohibition has clearly failed because the unregulated marketplace is flourishing and consumption rates are at an all-time high. According to estimates, some 500,000 Swiss regularly consume cannabis products — or about 6% of the country’s eight million residents.

If the proposal is fully approved by the National Council, it would move next to the Council of States, the upper body of Switzerland’s Federal Assembly.

Switzerland decriminalized minor cannabis possession (up to 10 grams) in 2012 although possession is still penalized by a flat civil fine of 100 Swiss francs. Cannabis containing just 1% or less THC, however, has been legal for manufacturing and distribution in Switzerland since 2011.

End


Massachusetts Opens Up Hemp & Cannabis Cultivation on Protected Farmlands

The Massachusetts Department of Agricultural Resources (MDAR) last week released guidance under a 2020 plan to allow cannabis and hemp cultivation on land belonging to the state Agricultural Preservation Restriction (APR) and Farm Viability Enhancement programs. The move could open up more than 73,000 acres of protected farmland to potential industry operations.

The APR program, which dates back to 1979, offers to pay farmland owners the difference between fair market value and the agricultural value of their farms in exchange for permanent deed restrictions in order to preserve farmland for agricultural use in the future, according to the agency website. The Farm Viability Enhancement Program provides business and technical assistance to established farmers through grant funding in exchange for signing an agricultural covenant on the property to keep it for agricultural use, according to the state website.

Hemp and cannabis production will be allowed on lands in the programs, although cannabis may not be grown on land that is federally funded as cannabis remains federally outlawed. MDAR noted to the Worchester Business Journal that all of the recently acquired APRs were obtained through federal financing.

In the guidance, the agency said the updated rules were sparked by “concerns” from landholders who sought to “diversify land use and provide new income sources.”

“After reviewing these concerns and evaluating the evolving state of the law as it relates to the legalization of medical and adult use marijuana in Massachusetts and cultivation of hemp in the United States, the Department has been reviewing its policies related to hemp and marijuana and evaluating whether the Department may recognize such activities as horticultural uses in a manner consistent with the laws and intent of the APR Program.” – Massachusetts Department of Agricultural Resources, “Hemp and Marijuana Production on APR and Farm Viability Protected Lands, Apr. 28, 2021”

Other hurdles remain for farmers, including an MDAR restriction on hemp-derived CBD products in Massachusetts‘ licensed cannabis stores. MDAR is presently working with the Massachusetts Cannabis Control Commission to address the issue, possibly opening the profitable market up to help farmers.

According to Vote Hemp, there were 202 acres of hemp grown in Massachusetts last year, up from just 21 in 2019.

Lukas Barfield contributed to the reporting in this article.

End


Tilray & Aphria Merge to Become Largest Cannabis Corporation

Canadian cannabis firms Tilray and Aphria have closed on the previously announced business combination with the new company operating as Tilray. The combined company – lauded at the announcement of the deal last year as the world’s largest cannabis company based on pro forma revenue – has a market capitalization of about $8.2 billion based on April 30 close stock prices.

Shares of the combined company will commence trading on the Toronto Stock Exchange and Nasdaq Global Select Exchange under the “TLRY” symbol on Wednesday.

Irwin D. Simon, Aphria’s chairman and CEO, will lead the combined firm. Tilray’s current director and former CEO Brandon Kennedy will serve on the combined company’s board of directors.

“Our focus now turns to execution on our highest return priorities including business integration and accelerating our global growth strategy. Covid-19 related lockdowns have presented unique challenges across Canadian and German markets. As these markets begin to re-open, Tilray is poised to strike and transform the industry with our highly scalable operational footprint, a curated portfolio of diverse medical and adult-use cannabis brands and products, a multi-continent distribution network, and a robust capital structure to fund our global expansion strategy and deliver sustained profitability and long-term value for our stakeholders.” – Simon in a press release

Under the terms of the agreement, Aphria shareholders received 0.8381 shares of Tilray for each Aphria common share.

The company said it expects to see an estimated $81 million of annual pre-tax cost synergies within 18 months and plans to achieve cost synergies in the areas of cultivation and production, cannabis and product purchasing, sales and marketing, and corporate expenses.

End


Maryland Police Can No Longer ‘Stop and Frisk’ Based on Cannabis Odor

A Maryland appeals court has ruled that law enforcement officers in the state can no longer stop people based on the odor of cannabis alone and that police need “reasonable suspicion” that a crime is being committed before they can even detain someone, according to a USA Today report. The court’s decision hinged on the fact that possession of small amounts of cannabis is decriminalized in the state.

“Because an officer cannot tell by the smell of marijuana alone that a person is involved in criminal activity, we hold that the odor of marijuana, by itself, does not provide reasonable suspicion to conduct an investigatory stop.” –  Judge Kathryn Grill Graeff, in the Appeals Court opinion, via USA Today

The appeal came in the case of a case in Prince George’s County, during which an officer responded about a group of males hanging out in an apartment complex and when the officer arrived, he smelled a “strong odor” of cannabis and patted down members of the group, ultimately recovering a handgun.

Michele Hall, who defended the then-juvenile in court, successfully argued that “the smell of marijuana is not enough to stop an individual on the street” and claimed that the odor of cannabis is often used as a pretext to justify further investigation, particularly in communities of color.

The Appeals Court in 2019 ruled that law enforcement officers in the state cannot make an arrest based on the odor of cannabis alone but the ruling didn’t go so far as to prevent officers from searching a vehicle based on the odor of cannabis. State case law, the judges determined, dictates there is a reduced expectation of privacy in a motor vehicle and the court’s opinion did not challenge that law.

A subsequent decision by the court last year determined that police could use cannabis odor as justification for a vehicle search but that they cannot search anyone in the vehicle unless they find evidence of a crime which does not include finding a small amount of cannabis.

End


Washington Drug Possession Reforms Await Gov.’s Signature

The Washington State Legislature delivered a bill to Gov. Jay Inslee that will overhaul the state’s drug possession laws and provide more resources for treatment, according to King 5 News. SB 5476 — which the governor is expected to sign in the coming days — was crafted in response to the State Supreme Court throwing out felony drug possession statutes in February.

Under the bill, simple drug possession would be a gross misdemeanor rather than a felony, with the option for prosecutors to divert the first two offenses. The burden of creating treatment options will fall largely on local governments and the misdemeanor penalty will sunset in two years, replaced by civil infractions. According to the report, $88.5 million will be earmarked for treatment options, mental health services, and “stabilization” for Washingtonians experiencing homelessness. Additionally, the bill instructs courts to hire “commissioners” to help sort out the issues caused by the Supreme Court’s decision.

In a statement after the bill passed the House, primary sponsor Sen. Manka Dhingra (D) said:

“This bill is not an ideal solution, but it is a thoughtful step forward. It achieves three important goals. First, it establishes a statewide approach to addressing drug possession. Second, it prioritizes and funds treatment for substance use disorder. And third, it provides us the time to come up with a public health approach to substance use disorder that relies on best practices and access to treatment that takes into account equity.” — Sen. Manka Dhingra via press release

However, many are skeptical of the new law including former prosecutor Bob Scales, who told King 5 he believes lowering the penalties for drug possession will not “incentivize” people to get treatment.

“And realistically,” he said, “because the prosecutor has to divert the first two cases, it will essentially be more administrative work. But I don’t think it will have any positive impact on public health or public safety.”

Washington‘s new law does not go as far as Oregon‘s successful November voter initiative that lowered simple drug possession to just a civil infraction or $100 fine.

End


GW Pharmaceuticals Receives Prestigious Queen’s Award for Innovation

London, England’s GW Pharmaceuticals, the makers of the cannabis-derived anti-seizure medication Epidiolex, has won the Queen’s Award for Enterprise 2021 in the Innovation category. It’s the first medical cannabis company to receive the award, which is considered the most prestigious for U.K. businesses.

Dr. Geoffrey W Guy, GW founder and chairman, said the company was “honored” to receive the award and that when he and co-founder Dr. Brian Whittle founded the company 23 years ago, its mission “was to improve the lives of seriously ill patients by unlocking the potential of the cannabis plant through rigorous scientific investigations and extensive clinical trials in order to obtain regulatory approval for such medicines to benefit patients.”

GW CEO Justin Gover said over the two decades the company “established a world-leading position in cannabinoid science and brought breakthrough medicines to patients in a new frontier of medicine.”

“We are immensely proud to have that work and dedication recognized by the prestigious Queen’s Awards for Enterprise. Our continued commitment to research and development has resulted in the treatment of thousands of patients with our medicines, and the prospect of helping countless more families through our robust pipeline of early- and late-stage product candidates.” – Gover in a press release

The company said it has invested more than £1.3 billion (USD$1.8 billion) “in the research, development and infrastructure needed to bring novel, innovative medicines to patients.”

In the announcement in the London Gazette, the company was described as “harnessing cannabinoid science to create innovative, regulatory approved, world-first cannabis-based medicines to improve lives.” The Queen’s Awards are in their 55th year.

In January, GW said that in 2020, Epidiolex sales increased more than 70%. It is also conducting trials on a multiple sclerosis drug in the U.S., Nabiximols, and it hopes to achieve data from at least one of the trials this year.

End


Bill to Legalize Psilocybin Therapy Introduced in Maine

A bill filed in Maine would legalize psilocybin mushroom therapy without a medical diagnosis, and allow adults 21-and-older to legally buy the psychedelic and use it under the supervision of a certified psilocybin service practitioner, according to the Dales Report.

The measure would include a 15% tax on retail sales of psilocybin products and allow manufacturing in a vertically-integrated model. The measure directs the state Department of Health and Human Services to establish guidelines for psilocybin treatment, such as personal possession restrictions, product testing, and standards for psilocybin care providers.

The bill says that those recommendations should be designed “to otherwise make this Act as consistent as possible in substance to the laws governing psilocybin in Oregon,” the report says. During the November 2020 election, Oregon voters approved a measure to legalize psilocybin therapy and Washington, D.C. voters moved to decriminalize all psychedelic plants, representing a watershed moment for psychedelic drug reforms.

In February, New Jersey Gov. Phil Murphy signed legislation to reduce the penalties for the possession of psilocybin mushrooms from a third-degree crime to a disorderly person offense. Lawmakers in Missouri and California are also considering bills to add psychedelics to the state’s Right to Try law, and decriminalize the substances, respectively.

The Maine measure was referred to the state legislature’s Joint Health and Human Services Committee.

A separate bill already filed in the state would decriminalize all currently illegal drugs, subjecting offenders to a $100 civil fine rather than jail time, according to the Dales Report. The fine could be waived if a person were to undergo a health assessment.

End


South Dakota Supreme Court Hears Cannabis Legalization Challenge

The South Dakota Supreme Court on Wednesday heard arguments in the challenge to the voter-approved ballot initiative to legalize cannabis in the state, the Brookings Register reports. Lawyers for the plaintiffs argued that the constitutional amendment violates the one-subject rule for initiatives and that the law would elevate the Department of Revenue to a fourth branch of government.

In February, Circuit Judge Christina Klinger ruled in favor of the plaintiffs and struck down the reforms. She determined that the amendment violated the one-issue clause associated with constitutional amendment ballot questions.

Brendan Johnson, an attorney representing South Dakotans for Better Marijuana Laws and other activists, argued that while the amendment was lengthy, it does not mean it should be disqualified and that there would be “damage” if the state’s highest court “literally throws out 417,000 votes that were cast on a piece of legislation,” according to the report.

Republican Gov. Kristi Noem has strongly opposed the measure and in an executive order issued in January the governor said the plaintiffs in the case – Highway Patrol Superintendent Col. Rick Miller and Pennington County Sheriff Kevin Thom – had standing to sue over the amendment because they are acting on her behalf.

Noem applauded the Circuit Court decision as protecting and safeguarding the state’s constitution. She said at the time she was “confident” the state’s highest court would come to the same conclusion as the lower court.

The measure was approved by 54% of voters during the 2020 General Election and was set to take effect July 1. The court could strike down the law entirely, keep parts of it that it determines do not violate the one-issue rule, or dismiss the lawsuit outright.

End


Washington Clarifies Delta-8 THC Not Legal Under Current Regulations

The Washington State Liquor and Cannabis Board (WSLCB) issued a policy statement this week to clarify that neither Delta-8 THC products nor the conversion of CBD, hemp products, or Delta-9 THC to Delta-8 THC, or any other cannabinoid, are currently allowed under Washington law.

In their statement, the LCB said it is aware of edibles and concentrates in Washington’s cannabis market that contain Delta-8 THC and has confirmed the presence of Delta-8 THC products in markets outside of their jurisdiction. According to the statement, the controlled substances section of the Revised Code of Washington (RCW) indeed regulates “cis – or trans tetrahydrocannabinol” and their optical isomers.

Regulators additionally cited the RCW covering unfair business practices and said, “It is an unfair or deceptive practice … for any person or entity to distribute … or sell to a purchaser any product that contains any amount of any synthetic cannabinoid.”

“For these reasons, delta-8 THC, as well as derivatives, extracts, cannabinoids, isomers, and CBD isolate from hemp or other sources that are genetically or chemically altered into compounds may not be produced or processed in LCB licensed facilities, and may not be sold in licensed marijuana retail stores.” — WSLCB policy statement excerpt

In the statement, the WSLCB raises other concerns about unnatural chemicals produced during Delta-8 THC synthesis, lacking concentration and potency thresholds, and a shortage of labs capable of testing for the cannabinoid. Despite their ban on “genetically or chemically” derived Delta-8, however, regulators said they will allow “cultivated” Delta-8 THC, seeming to carve out an exception for the cannabinoid if produced naturally by the cannabis plant.

Washington joins a growing list of states that have enacted or clarified cannabis industry rules related to the manufacturing and sale of Delta-8 THC products.

End


Oklahoma Pauses Seed-to-Sale Implementation Due to Lawsuit

A lawsuit filed by Oklahoma medical cannabis businesses has forced the state to put on hold the rollout of the seed-to-sale tracking program over claims the system would allow a single private business a monopoly, News On 6 reports. The state has tabbed Florida-based Metrc to run the system.

The tracking system was supposed to start today but on Thursday a judge issued a temporary restraining order against rolling out the program, which will remain in effect until the next hearing on June 29.

Attorney Ron Durbin, representing the state’s medical cannabis operators in the lawsuit, said that the plaintiffs “don’t have an issue with the seed-to-sell tracking program” but rather “an issue with the manner in which the state has adopted this one.”

“They are at least taking this seriously that they are going to look at this issue and that this needs to be something that is more and focused on the entire state.” – Durbin to News On 6

Brandon Rust, owner of Majestic Craft Cannabis, said he would like to see Metrc pushed out of Oklahoma and that too much money would be diverted to the out-of-state firm.

“This is really important that we fight back,” he said in the report. “We need the funds to stay in Oklahoma this needs to stay for the people.”

The Oklahoma Medical Marijuana Authority has not commented on the lawsuit; however, director Kelly Williams told News 4 earlier this month, prior to the filing of the legal challenge, that the seed-to-sale system would help “protect patient safety.”

End


Marlboro-Maker Phillip Morris Looking at ‘Smoke-Free’ Cannabis Options

Tobacco giant Phillip Morris — the international firm behind Marlboro-brand cigarettes — is warming up to the idea of entering the cannabis industry with what would likely be smoke-free cannabis products, according to a Bloomberg report.

In a recent interview, Phillip Morris’ CEO Andre Calantzopoulos said they are weighing the potential of a future cannabinoid-based offering. Specifically, the company is currently looking at cannabis’s efficacy/toxicity and is weighing the differences between pharmaceutical and consumer cannabis products. However, the still-nascent market’s lack of regulations has kept the company in only the planning stage, he said.

“We are doing all this work and will determine one day what avenues to pursue. But our priority is what we’re doing with our smoke-free products, and that’s where I would stay on cannabis.” — Calantzopoulos, in an interview with Bloomberg News

Phillip Morris announced a new “Beyond Nicotine” strategy earlier this year that will involve botanical-based products and a pivot away from cigarettes and smoking in general; they also teased the idea of sleep aid products, as well as offerings to promote calm and/or boosts of energy, during a February meeting of investors.

The Marlboro-maker would not be the first Big Tobacco firm to dabble in the cannabis space: earlier this year, British American Tobacco Chief Marketing Officer Kingsley Wheaton called CBD “an exciting growth area” for the company. And in 2018, Altria Group Inc. — the U.S.-based distributor of Marlboro cigarettes — invested a whopping $1.8 billion into The Cronos Group, a Canada-based cannabinoid producer and manufacturer.

End


Texas House Approves Medical Cannabis Expansions Bill

The Texas House on Wednesday granted approval to House Bill 1535, which seeks to expand the state’s limited medical cannabis program to include chronic pain patients, cancer patients, and people with PTSD, the Texas Tribune reports. The proposal also seeks to raise the THC limit for cannabis products in the program from 0.5% to 5% and would allow the Department of State Health Services to adopt new qualifying conditions for the program rather than relying on lawmakers to expand eligibility through the passage of new state laws.

The proposal is sponsored by Rep. Stephanie Klick (R-Fort Worth), who authored Texas’ original medical cannabis legislation in 2015. However, the current structure has been characterized by many advocates as a “medical CBD” program, not a medical cannabis program, and it has been made all but obsolete following the federal legalization of hemp and subsequent national proliferation of hemp-based CBD products.

Heather Fazio, Director of Texans for Responsible Marijuana Policy, told the Tribune that the increased THC limit is “a step in the right direction,” but she still called it an “incredibly restrictive cap.”

“Low levels of THC will work for some people but it doesn’t work for others. And so what we think is that doctors need to be the ones making these decisions, not lawmakers.” — Fazio, via the Tribune

The bill heads next to the Senate for consideration.

 

End


Philadelphia Bans Pre-Employment Drug Testing for Cannabis

The Philadelphia, Pennsylvania City Council has passed a measure to prohibit pre-employment drug screening for cannabis for most of the businesses in the city, according to a Patch.com report. Drug testing is still permitted for safety-sensitive positions such as law enforcement, childcare workers, those who oversee medical patients, and “any position in which the employee could significantly impact the health or safety of other employees or members of the public.”

Employees who are federally mandated to undergo pre-employment drug screenings are also exempt from the legislation. The bill also doesn’t prevent union employees from drug tests if it’s included in their collective bargaining agreements.

The bill, which was approved 15-1, “prohibits employers from requiring prospective employees to undergo testing for the presence of marijuana as a condition of employment, under certain terms and conditions.”

Councilmember Derek Green, the bill’s sponsor, noted prior to the vote last week that medical cannabis is legal in the state.

“We’re using pre-employment testing for a product that is being recommended by physicians, for individuals within the city of Philadelphia, that’s authorized for them to be used. That seems very contradictory.” – Green to the Philadelphia Inquirer

In 2019, Nevada became the first state to ban most employers from drug testing applicants for cannabis use during pre-employment. Washington, DC, Atlanta, Georgia, and New York City have also moved to limit employers’ ability to test most employees for off-the-clock cannabis use, according to Pre-Employ.com

Mayor Jim Kenney is expected to sign the bill into law, according to the Inquirer, and it would take effect January 1.

End


Syracuse University Announces Cannabis Industry Certificate Program

Syracuse University is partnering with cannabis education provider Green Flower on an industry certificate program, which will include three eight-week, fully online classes. The program will cover the Business of Cannabis, Agriculture and Horticulture, Law and Policy, and Healthcare and Medicine.

The announcement comes about a month after lawmakers passed, and Gov. Andrew Cuomo (D) signed, cannabis legalization reforms.

Michael Frasciello, dean of University College, said the “new market-sensitive certificates” represent the university’s “role in supporting growth-oriented economic initiatives in New York state.”

University College is the academic college of continuing education and professional studies at Syracuse University. These certificates are meant to complement existing credentials and advance the knowledge and practice of cannabis for professionals across multiple sectors, the University said in a press release.

Green Flower has also partnered with Florida Atlantic University on a six-month, non-credit certificate program. Its other academic partners include Northern Michigan University, the University of California at Riverside, the University of San Diego, Mount Aloysius College, Northwest Missouri State University, Western Washington University and St. Joseph’s University according to a University Business report.

“We saw the commitment by the university of expanding offerings for working adults and lifelong learners as an obvious sign that the university wants to serve all types of students in every stage of their growth and careers.” – Daniel Kalef, Green Flower vice president of higher education, in a statement.

“With the new legalization of cannabis in New York and neighboring states, cannabis knowledge and education will be in high demand and extremely popular as people begin to navigate the legal cannabis landscape and find ways to be a part of the predicted record growth,” he said.

End


Number of Cannabis-Friendly Banks in Massachusetts Has Doubled Since 2018

There are at least six financial institutions serving Massachusetts’ cannabis industry – double the number from just three years ago, MassLive reports. The new banking institutions include Eastern Bank, which is taking over Century and its cannabis division, and Avidia Bank, but Cannabis Control Commission Chair Steven Hoffman declined to name the third.

“I continue to have conversations … with new banks who are starting due diligence around entering the industry. We will continue to see new entrants.” – Hoffman to MassLive

In 2018, just Century, BayCoast Bank, and GFA Federal Credit Union served cannabis clients. Hoffman noted that he knows that, given federal law, “any bank that is servicing the cannabis business is taking some risk” but that he is “grateful for those who have stepped up because they have made an incredible contribution to public safety.”

Last week, the U.S. House of Representatives passed – for the second time in as many sessions – the SAFE Banking Act which would remove that risk from the equation for financial institutions as it would explicitly allow state-approved cannabusinesses to access financial services.

That bill was squashed last session by the then-Republican-led Senate.

Gary Vierra, senior vice president and chief risk officer for BayCoast, said some of its clients are “looking for a lending relationship.”

“With the risk of the industry, there is a lot of restrictions in the space. Our commercial lending group underwrites,” he said to MassLive. “We require the relationship be with us so we can oversee it from a compliance standpoint as well.”

Last month, the federal Financial Crimes Enforcement Network (FinCEN) reported that, as of November 2020, 515 banks and 169 credit unions served the cannabis industry nationwide. The number of banks and credit unions had initially fallen from November 2019 to December 2020.

End


Veronica Castillo: Plant-Based Living & Creating Your Own Cannabis Career

In this episode of Fresh Cut, host Cara Wietstock meets with Veronica Castillo, also known as Vee, who is a contributor to numerous cannabis industry publications including Ganjapreneur, as well as the founder of the Traveling Vegan Cannabis Writer Blog. For her blog, Vee takes onsite assignments at cannabis businesses all around the country — allowing her to experience their operations first-hand and share their knowledge and expertise with the world. Cara and Vee also discuss plant-based living, from practicing veganism to microdosing hallucinogenic mushrooms.


To learn more about Vee and read about where she’s headed next, visit her website!

 

End


Louisiana Cannabis Legalization Bill Advances to House Floor

Lawmakers in Louisiana’s House Administration of Criminal Justice Committee voted 7-5 yesterday in favor of advancing House Bill 524, the state’s adult-use cannabis legalization proposal.

The bill now advances to the House floor for consideration although it is expected to face heavy opposition in the Republican-controlled body. If approved there, it would face further opposition in the Senate and then potentially from Gov. John Bel Edwards (D), who has said he supports medical cannabis but opposes adult-use legalization.

“As I almost always do, I’ll take a bill as it arrives on my desk and see what it contains. I’m not going to speculate now on that. But I do have great interest in that bill and what it says especially if it does make it up to the fourth floor.” — Gov. Edwards, in a statement on Tuesday, via The Advocate

The bill originally would have put the legalization question to voters as a November 2022 referendum and then decriminalized cannabis if voters approved the reforms, but the primary sponsor Rep. Richard Nelson (R) later shifted away from that strategy. The now-updated legislation instead would allow municipalities to opt out of the industry at the local level.

Despite many lawmakers’ opposition, a two-thirds majority of Louisiana voters support legalizing adult-use cannabis, according to a recent poll.

Committee members yesterday also advanced cannabis decriminalization legislation in a 6-5 vote that — like the aforementioned voter referendum plan — would only take effect if lawmakers first approve a plan to legalize and regulate adult-use cannabis.

End


Vermont Joins List of States to Ban Delta-8 THC

The Vermont Agency of Agriculture, Farms, and Markets (AAFM) informed all registered hemp cultivators that Delta-8 THC products are not regarded as legal hemp products in an email sent out last Friday, April 23.

With this statute, Vermont joins 12 other states that have categorized the manufacturing and sale of Delta-8 THC products as illegal under state law; Delta-8 THC has also been banned in Alaska, Arizona, Arkansas, Colorado, Delaware, Idaho, Iowa, Mississippi, Montana, Rhode Island, and Utah.

On their website, Vermont AAFM clarifies the state’s position further by acknowledging that hemp plants naturally produce Delta-8 THC in trace amounts. However, products with intoxicating levels of the cannabinoid are created using isomerization, which synthetically converts CBD to THC.

The Vermont Hemp Rules state that, “A processor shall not use synthetic cannabinoids in the production of any hemp product or hemp-infused product” (6.3). With this rule, the manufacturing, labeling, or sale of any Delta-8 product in the state of Vermont would violate state law. As such, anyone who distributes, uses, or possesses one of these products may face criminal penalties in the state.

Many CBD retailers have seen great financial gains due to the recent proliferation of Delta-8 throughout the states. This clarification may heavily impact their newfound revenues.

Meanwhile, the hemp industry in Alabama recently praised lawmakers there after they pulled an amendment proposal that would have categorized Delta-8 THC and Delta-10 THC as controlled substances.

Editor’s note: A previous version of this article incorrectly stated that Kentucky was among the states that have banned Delta-8 THC products.

End


Maryland Medical Cannabis Sales Surpass $1 Billion

40 months after its 2017 launch, Maryland’s medical cannabis market has reached the milestone of $1 billion in sales, the Baltimore Business Journal reports.

Quarterly sales have steadily grown from year to year in Maryland, with sales nearly doubling from $60.5 million in 2019 to $115 million in 2020. This year alone, dispensaries have raked in $135 million in the first three months, setting a pace to reach $500 million by the end of the year, according to the report.

Maryland Medical Cannabis Commission (MMCC) Executive Director William Tilburg said he believes the increased number of medical cannabis patients and dispensaries have led to the growing sales figures (registered cannabis patients in Maryland grew from 87,019 to 123,376 from December 2019 to December 2020). Those impressive growth numbers were followed by another 1,959 patients signing up for medical cannabis in January, bringing Maryland’s total patient number to 125,335. Additionally, dispensary numbers have increased by about 10 percent over that same time period.

Tilburg said he believes the next billion will come much faster due to Maryland’s likely next step of legalizing adult-use cannabis sales.

Although Maryland failed to pass adult-use reforms this session, the state is nonetheless predicted to follow in the footsteps of nearby New York, New Jersey, and Virginia with a new pass on the reforms next year. If Maryland passes adult-use cannabis, cannabis market research firm BDS Analytics predicts the state could reach its next billion in sales by 2024, with recreational sales accounting for two-thirds of the total, according to the report.

End


Minnesota Committee Advances Cannabis Legalization Bill

Lawmakers in Minnesota’s House Public Safety and Criminal Justice Reform Finance and Policy Committee advanced the state’s cannabis legalization proposal in an 11-7 vote on Tuesday, Marijuana Moment reports. It was the ninth House committee so far to advance the proposal along its path to the full House floor.

The bill — sponsored by House Majority Leader Ryan Winkler (D), Speaker Melissa Hortman (D), and others — seeks to legalize the possession and regulated sale of cannabis products for adults aged 21 or older and would allow adults to grow up to eight cannabis plants (four mature and four immature) at home.

“Our effort as a society and as a state to use the criminal justice system to ban, prohibit and criminalize cannabis is a public policy failure. As a public safety and criminal justice matter, cannabis prohibition has had a disproportionate effect on communities of color, especially Black Minnesotans. Our [current] policy is a failure and it creates harm. This bill is about correcting that harm of cannabis prohibition using the criminal justice system.” — Winkler, in a statement before the vote

The committee added several amendments to the bill, according to the report, including one that clarifies a person caught possessing cannabis in excess of the personal possession limit of 1.5 ounces would face lower penalties if said cannabis product has a legal source (as opposed to an illegal/unregulated source). Another amendment adds language to the bill’s expungement provision that calls on courts to automatically vacate and dismiss records for low-level possession cases.

The proposal now moves to the House Health Finance and Policy Committee.

If the bill is ultimately approved by the House, it is expected to face steep opposition in the Republican-controlled Senate.

End


Members of Congress Request Hemp Display in U.S. Botanic Garden

Three members of Congress have sent a letter to the executive director of the Washington, D.C.-based U.S. Botanic Garden seeking to have hemp plants on display. The letter was sent by Democratic Reps. Eleanor Holmes Norton (DC), Barbara Lee (CA), and Earl Blumenauer (OR).

If approved, it would be the first time the Botanic Garden would display cannabis in its collection.

“Hemp has a long history of cultivation in the U.S. Hemp was grown by most of the Founders, and in 2018, George Washington’s Mount Vernon Estate harvested its first hemp crop since 1799. All ships in every war prior to World War II had ropes and sails made from hemp grown in the U.S. Until the Marijuana Tax Act of 1937, which was found to be unconstitutional in 1969, hemp was a major agricultural commodity in the U.S. Given that hemp is legal and enjoys national, bipartisan support, now is an appropriate time for the Botanic Garden to display hemp plants.” – Reps. Norton, Lee, and Blumenauer in the April 20 letter

Blumenauer is one of the founding members of the Congressional Cannabis Caucus and Lee joined the group during the 116th Congress after Jared Polis left Congress following his successful bid for governor of Colorado.

The letter notes that hemp was federally legalized in 2018 following the passage of the Farm Bill.

“The market has grown exponentially since the implementation of the pilot programs and some expect the market to reach $26.6 billion by 2025,” the letter states, noting the differences between industrial hemp and THC-rich cannabis – which remains federally outlawed.

The representatives have asked for a response to the request by May 4.

End


New York Tribes Making Post-Legalization Plans

At least two New York Native American tribes are looking to get into the state’s cannabis industry following the legislature-approved reforms last month, Syracuse.com reports. Other New York-based Native American Nations have not released statements on their post-legalization plans.

Long Island’s Shinnecock Indian Nation plans to break ground on a cannabis facility in the next few weeks – with hopes of rolling out sales later this year – while the Saint Regis Mohawks are considering an ordinance to allow sales on its territory in Franklin County.

New York government officials have indicated they do not anticipate sales until next year.

The Saint Regis Mohawk Tribe recently sent cease and desist orders to unlicensed and unregulated cannabis dispensaries operating in its jurisdiction, the Plattsburgh Press-Republican reports. Until the tribe approves an ordinance, cannabis sales remain a violation of tribal law, the Nation said in a statement. Officials also urged residents “to refrain from purchasing any goods from these unregulated establishments for their own safety.”

Other New York tribes have not yet indicated their plans following broad legalization in the state. Central New York’s Oneida Indian Nation Vice President for Communications, Joel Barkin, told Syracuse.com that the tribe is “studying the idea.”

The Seneca Nation of Indians President Rickey Armstrong Sr. told Buffalo’s WKBW in 2019 that the tribe is “like a snake ready to strike” on legal cannabis opportunities and that the Tribal Council would “pull the trigger whenever they feel appropriate.” The Seneca Nation is based in Western New York.

In all, there are eight federally recognized tribes in the state.

End